??????????????????????????????

????

□□□□□□ Pharmacokinetics□ PK □□□□□□□

□□□

□□□

PK
/ PD
/ -
/ -

PK

PK PD

Maximum Tolerated Dose, MTD
MTD / /

PK PK
-

???????

/ PK
PK

PK 3

/ / /

PK PD -
PD
-

PK
/

???????

PK □□□□

□□□

□□□□□□□□ PK □□□□□□□□□□□□□ $C_{min,ss}$□ $C_{max,ss}$□ $C_{av,ss}$□ $AUC_{□\ 0\text{-}t□}$ □□□□□□□□ DF□□□□□□□□□□ PK □□□□□□□□□□□□□

Rev.1/ Committee for Medicinal Products for Human Use (CHMP) 20 July 2017.

[4] European Medicines Agency. Guideline on the use of pharmacogenetic methodologies in the pharmacokinetic evaluation of medicinal products EMA/ CHMP/37646/2009 Committee for Medicinal Products for Human Use (CHMP) 12 December 2011.

[5] .9012 .2020.

Revision #1
Created 2025-11-23 01:29:18 UTC by Colin Wang
Updated 2025-11-23 02:25:22 UTC by Colin Wang